Zydus Cadila Gets Approval from USFDA to Market Anti- Depressant Drug

The USFDA has given its final approval to Zydus Cadila to market Mirtazapine Orally Disintegrating Tablets USP in strengths of 15 mg, 20mg, and 45mg, said Cadila Healthcare in a BSE filing on Monday.
 
The drug is an anti-depressant and will be produced at the group’s formulations manufacturing facility at Baddi.
 
The group has so far filed over 300 ANDAs and now has more than 115 approvals, since the commencement of the filing process in FY 2003-04, it added.
 
Trading at Rs 497, Cadila Healthcare Limited was up by Rs 2.45 or 0.50% as at 10.17 on Monday, on the BSE. The stock had hit a high of Rs 500.